Biogen beats top-line and bottom-line estimates; updates FY26 outlook

Celcuity plans late Q3 2026 REVTORPYK shipments and targets sNDA submission in Q3 2026

HawkEye 360 outlines $215M-$220M 2026 revenue outlook while targeting 10-minute revisit and latency in 2-3 years

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

The Stock Market Just Made a Move That Warren Buffett Has Warned About. History Says Investors Should Make This 1 Move.